2.68 0.02 (0.75%) | 03-28 11:27 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.14 | 1-year : | 3.66 |
Resists | First : | 2.69 | Second : | 3.14 |
Pivot price | 2.59 | |||
Supports | First : | 2.53 | Second : | 2.44 |
MAs | MA(5) : | 2.65 | MA(20) : | 2.59 |
MA(100) : | 2.32 | MA(250) : | 2.63 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 85.9 | D(3) : | 81.4 |
RSI | RSI(14): 67.2 | |||
52-week | High : | 7.18 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KNTE ] has closed below upper band by 8.0%. Bollinger Bands are 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.68 - 2.69 | 2.69 - 2.71 |
Low: | 2.6 - 2.62 | 2.62 - 2.64 |
Close: | 2.63 - 2.66 | 2.66 - 2.69 |
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Thu, 28 Mar 2024
Kinnate Biopharma Inc. (NASDAQ:KNTE) Short Interest Down 43.6% in March - MarketBeat
Mon, 25 Mar 2024
2024-03-25 | NDAQ:KNTE | Press Release | Kinnate Biopharma Inc - Stockhouse Publishing
Fri, 22 Mar 2024
Citigroup Inc. Purchases 419,795 Shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) - MarketBeat
Fri, 22 Mar 2024
Citigroup Inc. Buys 419795 Shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) - Defense World
Wed, 13 Mar 2024
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... - Business Wire
Fri, 01 Mar 2024
Kinnate Biopharma Strikes Major Deal on Drug Rights - TipRanks.com - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 47 (M) |
Shares Float | 23 (M) |
Held by Insiders | 0.1 (%) |
Held by Institutions | 82.5 (%) |
Shares Short | 825 (K) |
Shares Short P.Month | 1,100 (K) |
EPS | -2.78 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.66 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -33.7 % |
Return on Equity (ttm) | -55.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -2.8 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -106 (M) |
Levered Free Cash Flow | -60 (M) |
PE Ratio | -0.97 |
PEG Ratio | 0 |
Price to Book value | 0.73 |
Price to Sales | 0 |
Price to Cash Flow | -1.2 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |